GSK.N
Latest Trade
45.51USDChange
0.30(+0.66%)Volume
502,209Today's Range
-
45.5752 Week Range
-
46.01As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 45.21 |
|---|---|
Open | 45.40 |
Volume | 502,209 |
3M AVG Volume | 56.58 |
Today's High | 45.57 |
Today's Low | 45.28 |
52 Week High | 46.01 |
52 Week Low | 36.42 |
Shares Out (MIL) | 4,988.72 |
Market Cap (MIL) | 113,507.90 |
Forward P/E | 14.24 |
Dividend (Yield %) | 4.46 |
GSK seeks FDA approval for investigational HIV treatment
Hikma Pharmaceutical Says Completed FDA Response For Generic Advair
Exagen Inc Extends Collaboration Agreement With Glaxosmithkline For A Third Year
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Industry
Major Drugs
Executive Leadership
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Vaccines
Brian McNamara
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM) | 18.46 |
|---|---|
Price To Sales (TTM) | 2.61 |
Price To Book (MRQ) | 7.34 |
Price To Cash Flow (TTM) | 10.37 |
Total Debt To Equity (MRQ) | 280.74 |
LT Debt To Equity (MRQ) | 210.95 |
Return on Investment (TTM) | 11.20 |
Return on Equity (TTM) | 7.30 |
GlaxoSmithKline Plc said on Thursday its HIV unit has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for fostemsavir, an experimental treatment for HIV in adults.
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.
German science and technology company Merck KGaA <MRCG.DE> raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials <VSM.N> in October.
GlaxoSmithKline PLC on Tuesday said it had reached an eve-of-trial settlement resolving claims by several insurers that it misled them into paying $2.7 billion for drugs made at a Puerto Rico plant in an "egregious" violation of federal manufacturing standards.
GlaxoSmithKline Plc is set to face trial on Tuesday in a multibillion-dollar lawsuit alleging it misled insurers into paying for drugs made in "egregious" violation of federal quality standards, with a lawyer better known for securing big verdicts against drugmakers leading...
GlaxoSmithKline <GSK.L> on Wednesday raised its annual profit forecast for the second time this year as sales of its shingles vaccine beat expectations and older medicines, including HIV treatments, continued to sell well.
GlaxoSmithKline Plc on Wednesday raised its annual profit forecast for the second time this year as soaring sales of its Shingles vaccine helped offset a hit from generic competition to its blockbuster asthma drug Advair.
GlaxoSmithKline Plc said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection.
GlaxoSmithKline Plc on Friday won access to data underlying a published study funded by plaintiffs lawyers suing the drugmaker, which found a correlation between use of its onetime anti-nausea drug Zofran during pregnancy and birth defects.
By Nate Raymond A federal judge on Thursday rejected GlaxoSmithKline Plc's bid to dismiss claims by a subset of the hundreds of women who say the company failed to warn them that the anti-nausea drug Zofran can cause birth defects.
GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.
GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.
The U.S. Food and Drug Administration and international health authorities are investigating the safety of Zantac heartburn medicine, also sold generically as ranitidine, after finding a probable cancer-causing impurity in the drug.
GlaxoSmithKline will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said on Monday, as it looks to bolster its push into the lucrative cancer drug market.
GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).
GlaxoSmithKline <GSK.L> on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug.
GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.
Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.
Vectura Group said on Friday a British court had ruled in its and partner Sandoz's favour over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.